Terms: = Germ cell tumor AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
313 results:
1. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract] [Full Text] [Related]
2. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Sakunrangsit N; Khuisangeam N; Inthanachai T; Yodsurang V; Taechawattananant P; Suppipat K; Tawinwung S
Cancer Immunol Immunother; 2024 Apr; 73(6):98. PubMed ID: 38619641
[TBL] [Abstract] [Full Text] [Related]
3. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
4. Identification of genetic modifiers enhancing B7-H3-targeting car T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract] [Full Text] [Related]
5. Intraventricular carv3-TEAM-E T cells in Recurrent Glioblastoma.
Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
[TBL] [Abstract] [Full Text] [Related]
6. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
7. Locoregional delivery of IL-13Rα2-targeting car-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
[TBL] [Abstract] [Full Text] [Related]
9. Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche.
de Oliveira KG; Bång-Rudenstam A; Beyer S; Boukredine A; Talbot H; Governa V; Johansson MC; Månsson AS; Forsberg-Nilsson K; Bengzon J; Malmström J; Welinder C; Belting M
Acta Neuropathol Commun; 2024 Feb; 12(1):35. PubMed ID: 38414005
[TBL] [Abstract] [Full Text] [Related]
10. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
11. Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
[TBL] [Abstract] [Full Text] [Related]
12. Nanocatalytic Anti-tumor Immune Regulation.
Li M; Jiang H; Hu P; Shi J
Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202316606. PubMed ID: 38212843
[TBL] [Abstract] [Full Text] [Related]
13. Immune determinants of car-T cell expansion in solid tumor patients receiving GD2 car-T cell therapy.
Kaczanowska S; Murty T; Alimadadi A; Contreras CF; Duault C; Subrahmanyam PB; Reynolds W; Gutierrez NA; Baskar R; Wu CJ; Michor F; Altreuter J; Liu Y; Jhaveri A; Duong V; Anbunathan H; Ong C; Zhang H; Moravec R; Yu J; Biswas R; Van Nostrand S; Lindsay J; Pichavant M; Sotillo E; Bernstein D; Carbonell A; Derdak J; Klicka-Skeels J; Segal JE; Dombi E; Harmon SA; Turkbey B; Sahaf B; Bendall S; Maecker H; Highfill SL; Stroncek D; Glod J; Merchant M; Hedrick CC; Mackall CL; Ramakrishna S; Kaplan RN
Cancer Cell; 2024 Jan; 42(1):35-51.e8. PubMed ID: 38134936
[TBL] [Abstract] [Full Text] [Related]
14. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract] [Full Text] [Related]
15. car NK cell Therapy for the treatment of Metastatic Melanoma: Potential & Prospects.
Hibler W; Merlino G; Yu Y
Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
[TBL] [Abstract] [Full Text] [Related]
16. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
[TBL] [Abstract] [Full Text] [Related]
17. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract] [Full Text] [Related]
18. α-Pyrrolidinononanophenone derivatives induce differentiated SH-SY5Y neuroblastoma cell apoptosis via reduction of antioxidant capacity: Involvement of NO depletion and inactivation of Nrf2/HO1 signaling pathway.
Sakai Y; Egawa D; Hattori J; Morikawa Y; Suenami K; Takayama T; Nagai A; Michiue T; Ikari A; Matsunaga T
Neurotoxicology; 2024 Jan; 100():3-15. PubMed ID: 38040126
[TBL] [Abstract] [Full Text] [Related]
19. CSPG4 car-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract] [Full Text] [Related]
20. Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma.
Gardam B; Gargett T; Brown MP; Ebert LM
Front Immunol; 2023; 14():1261257. PubMed ID: 37928547
[TBL] [Abstract] [Full Text] [Related]
[Next]
